Sign in

JN117

@jn117.bsky.social
89 followers 184 following 445 posts

I am a layman. I am interested in science, engineering, immunology, virology, COVID, and Long Covid. I am very grateful to researchers who are working to help us understand infection-associated chronic conditions.

PostsRepliesMedia
JN117 @jn117.bsky.social · 29/07/2026
I wonder if humans have broad enough immunity now that there are no easy gaps in our immunity for a variant to quickly exploit and rise to dominance.
020
JN117 @jn117.bsky.social · 17/05/2026
Double check that it still meets your needs. I found that I need more cushion than I did 30 years ago!
010
JN117 @jn117.bsky.social · 11/05/2026
Nice visualization. Thank you.
010
JN117 @jn117.bsky.social · 28/04/2026
And your companion essay "The 'false-positive PCR' problem is not a problem" was the best ever written on the topic! Many thanks for explaining so clearly. virologydownunder.com/the-false-po...
virologydownunder.com
The "false-positive PCR" problem is not a problem
There clearly is no PCR crisis or false positive plague or casedemic. The false-positive PCR problem is not a problem.
1102
JN117 @jn117.bsky.social · 24/03/2026
Wastewater disconnect from hospitalization? On Feb 14, wastewater analysis showed very high levels of infection in Minnesota, but there was limited impact on hospitalization for COVID-19. The hospitalization had been falling since December 28. Feb 15 showed 2.1 hospitalizations per 100K per week.
111
JN117 @jn117.bsky.social · 18/03/2026
New paper explains a new genetic analysis technique for discriminating direct animal-to-human spillover events versus lab-developed spillover events. Using this analytical approach, SARS-CoV-2 shows no evidence of lab-processing prior to infecting humans. (gift link) www.nytimes.com/2026/03/09/s...
nytimes.com
Scientists Get a Glimpse of How New Pandemics Are Made
020
JN117 @jn117.bsky.social · 18/03/2026
Great picture. You should share this during Office Hours!
000
JN117 @jn117.bsky.social · 16/03/2026
Mountain climber with LC "I want to share everything I can with others about my story. If there were a fairy that said "30/100 of the M&Ms in that bag are shit pebbles" I wouldn't have even stuck my hand in the bag. I'm the fairy. Avoid COVID. "
1103
JN117 @jn117.bsky.social · 16/03/2026
I'd be curious to know what your thoughts are. Instead of "safe", I'd probably say "has a good safety record." And instead of "effective", I'd try to quantify the protection--i.e. prevents 80% of hospitalizations, etc.
100
JN117 @jn117.bsky.social · 15/03/2026
When it comes to vaccines, the words "safe", "immunity" and "prevent" have caused incredible confusion and sparked endless debates. @kmpanthagani.bsky.social 's recent article does a great job explaining how misunderstandings arise. Recommended! www.youcanknowthings.com/when-work-do...
youcanknowthings.com
When “work” doesn’t work
I recently gave a talk on vaccine communication, and the most common feedback I got was appreciation for the section on words that confuse people. I’ve written before how a lot of “misinformation” ca...
154
JN117 @jn117.bsky.social · 10/03/2026
Happy TWiVersary :-) Thanks for letting us listen in on your discussions. I've learned a lot too!
000
JN117 @jn117.bsky.social · 10/03/2026
I wish the outcome had been very different. So disappointing.
010
JN117 @jn117.bsky.social · 08/03/2026
Either the authors or I am having a malfunction -- I do not see the graphs/figures anywhere in the paper nor on the web site.
000
Reposted by JN117
Kristen Panthagani, MD, PhD @kmpanthagani.bsky.social · 02/03/2026
RFK uses many of the same rhetorical tricks over and over again. It’s tempting to play whack-a-mole with every rumor, but research shows a better (and less exhausting) method: “prebunking” — or teaching people to recognize the patterns used to sell falsehoods. Today's post does just that 👇🏽
1163
Reposted by JN117
Denis - The COVID Info Guy @thecovidinfoguy.bsky.social · 24/02/2026
Australia: "Most flu deaths this century were recorded in 2025, ABS finds" Last Year (2025): 🔹COVID-19: ~2,161 deaths 🔹Influenza: ~1,701 deaths 🔹RSV: ~582 deaths
abc.net.au
Most flu deaths this century were recorded in 2025, ABS finds
There were more deaths associated with influenza last year than any other year this century, according to the Australia Bureau of Statistics.
27037
JN117 @jn117.bsky.social · 23/02/2026
This was a really cool experiment. Thank you all for this excellent contribution to our understanding! (I've been reading "Air-Borne." It is just fascinating how understanding airborne transmission-- despite it crucial importance to our lives--has not been a greater focus of humanity's efforts.)
030
JN117 @jn117.bsky.social · 19/02/2026
Also, the "test negative" approach used in the study might only only detect sequelae that happen at a greater rate for COVID than for other respiratory illnesses. The comparator group all were all being tested for COVID, suggesting they had symptomatic viral illness.
010
JN117 @jn117.bsky.social · 19/02/2026
Not sure the study is capable of supporting the authors' conclusions. I don't think medical records ever capture when conditions go away. Probably the study is simply finding that most new Long Covid conditions are first diagnosed in the first year after infection.
271
JN117 @jn117.bsky.social · 03/02/2026
Surprisingly comprehensive article on recent research in Nordic countries showing health impacts of COVID-19 on cognitive problems, health care utilization, and rates of depression. www.sciencenorway.no/covid19-long...
sciencenorway.no
Researchers: Not testing for Covid-19 is creating problems
People have become sicker after the pandemic, but without Covid-19 testing it's difficult to understand why.
000
JN117 @jn117.bsky.social · 03/02/2026
Thank you for this research! It is interesting to see infection readily established in this study. Yet another recent study failed to cause influenza transmission using naturally infected people. Quite a puzzle. journals.plos.org/plospathogen...
journals.plos.org
Evaluating modes of influenza transmission (EMIT-2): Insights from lack of transmission in a controlled transmission trial with naturally infected donors
Author summary Human-to-human influenza virus transmission under controlled conditions could provide insights leading to better control of epidemics and pandemics. However, a previous study using labo...
000
JN117 @jn117.bsky.social · 18/01/2026
That is a nice summary. The full research article is here: wwwnc.cdc.gov/eid/article/...
000
JN117 @jn117.bsky.social · 16/01/2026
Thank you for explaining this.
110
JN117 @jn117.bsky.social · 09/01/2026
Very nice! Did this project require any outside air system (i.e. HRV/ERV)?
010
JN117 @jn117.bsky.social · 04/01/2026
I agree. They mention 28-week protection in this press release (which would cover flu season). There were 33 cases (2.8%) of flu in placebo group versus 8 (0.7%) in the CD388 group (450 mg dose). Conceptually, it reminds me of lenacapavir for prevention of HIV. www.cidara.com/news/cidara-...
cidara.com
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza - Cidara Therapeutics
020
JN117 @jn117.bsky.social · 04/01/2026
www.cidara.com Cidara Therapeutics is currently in a Phase 3 trial of a long-acting anti-viral against all strains of influenza. In earlier human testing (n=5,000), the preventive medication was 76% effective with a single 450 mg sub-cutaneous dose.
cidara.com
Targeted Immunotherapy for Transformative Outcomes - Cidara Therapeutics
021
JN117 @jn117.bsky.social · 04/01/2026
"CD388... is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation" "..is administered as a one-time 450-milligram subcutaneous dose" www.cidara.com/news/cidara-...
cidara.com
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations - Cidara Therapeutics
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu ...
000
JN117 @jn117.bsky.social · 04/01/2026
This is quite interesting. There is a Phase 3 pivotal trial with 6,000 people enrolled right now! CD388 is a one-time subcutaneous dose. www.cidara.com/news/cidara-...
cidara.com
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations - Cidara Therapeutics
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu ...
040
JN117 @jn117.bsky.social · 04/01/2026
Further in the article, they describe CD388 as "prevents the virus from unclipping , so that the virus is no longer infectious ... by attacking a protein that is essential for replication, the molecule works against every influenza mutation". So it is an anti-viral.
151
JN117 @jn117.bsky.social · 01/01/2026
Happy New Year!
010
Reposted by JN117
Chise @sailorrooscout.bsky.social · 28/12/2025
GOOD NEWS! Researchers have shown Alzheimer’s disease can be REVERSED- not just prevented. Using a potent neuroprotective compound called P7C3-A20, they found RESTORING balance to a central cellular energy molecule (NAD+) not only PREVENTED disease features but REVERSED them, EVEN at late stages.
219114734467
JN117 @jn117.bsky.social · 17/12/2025
By the way, Bluesky posted recently that they restored access to >18 in MS. bsky.app/profile/bsky...
130
Reposted by JN117
Paul Offit @pauloffit.bsky.social · 16/12/2025
open.substack.com/pub/pauloffi... What do you do if someone offers you $1 million dollars to debate vaccine safety?
open.substack.com
Debating Science: No Thanks
Anti-vaccine activists RFK Jr., Aaron Siri, and Steve Kirsch have asked that I debate them on vaccine safety. One of them offered me $1 million to do it. Here’s why I declined.
0317
JN117 @jn117.bsky.social · 15/12/2025
There is a new HHS web page about Lyme. www.hhs.gov/lyme/index.h...
hhs.gov
000
JN117 @jn117.bsky.social · 11/12/2025
There were some unpleasant common side effects. investor.lilly.com/news-release...
010
JN117 @jn117.bsky.social · 11/12/2025
Wishing you a speedy full recovery.
010
JN117 @jn117.bsky.social · 04/12/2025
Good point. Perhaps it is somewhat like the case where a nurse wrote to a TV actor suggesting he get a lump on his throat checked. www.today.com/today/amp/td...
today.com
How HGTV star Tarek El Moussa's cancer, spotted by fan, changed his life
Now in remission after a thyroid-cancer battle, the star of HGTV's "Flip or Flop" is thankful for a nurse who suggested a biopsy.
010
JN117 @jn117.bsky.social · 04/12/2025
you could track it down to a small number of houses or buildings and then seek individual permission to go further. That way it preserves informed consent, if that even applies.
130
JN117 @jn117.bsky.social · 04/12/2025
I would want to know. Pemgarda and Paxlovid would then be on my shopping list.
130
JN117 @jn117.bsky.social · 01/12/2025
Is COVID "mild"? In a study of 9,000 people who had COVID in 2024, COVID was so "mild" that 24-26% of people had at least one symptom lasting 84 days (fatigue, shortness of breath/respiratory distress, cough, or smell/taste disorder) that they don't have prior. www.shionogi.com/global/en/ne...
shionogi.com
New Clinical Data on the Efficacy of Antiviral Treatments for Post-COVID-19 Condition
000
JN117 @jn117.bsky.social · 30/11/2025
The 5 pre-specified symptoms were fatigue, dyspnea or respiratory distress, cough, smell disorder, taste disorder.
000
JN117 @jn117.bsky.social · 30/11/2025
Shionogi press release: An observational study found a reduction in incidence of post-COVID condition (PCC) in those who took anti-virals (26% versus 24%). PCC defined as persistence of any of 5 specified symptoms on both days 28 & 84. www.shionogi.com/global/en/ne...
shionogi.com
New Clinical Data on the Efficacy of Antiviral Treatments for Post-COVID-19 Condition
100
JN117 @jn117.bsky.social · 19/11/2025
A nice summary article on remission/cures of autoimmune disease in these initial small trials. It seems like various ways of depleting B cells are all working. The article mentions teclistamab, which I was not familiar with. www.medpagetoday.com/rheumatology...
medpagetoday.com
Myeloma Drug Performs Well in Autoimmune Diseases
Safety could be problematic, however
010
JN117 @jn117.bsky.social · 14/11/2025
Here are a few more details on this from the Stanford news release. Unfortunately, the research article seems paywalled. med.stanford.edu/news/all-new...
med.stanford.edu
Stanford Medicine scientists tie lupus to a virus nearly all of us carry
The Epstein-Barr virus can convert B cells it’s infected into diabolical overlords that reprogram myriad other immune cells to attack our tissues, Stanford Medicine scientists have found.
012
JN117 @jn117.bsky.social · 14/11/2025
This seems like a significant breakthrough in understanding lupus pathogenesis. It connects EBV infection to the disease. Stanford has licensed the technology to a startup, EBVio Inc, founded by the scientists. med.stanford.edu/news/all-new...
med.stanford.edu
Stanford Medicine scientists tie lupus to a virus nearly all of us carry
The Epstein-Barr virus can convert B cells it’s infected into diabolical overlords that reprogram myriad other immune cells to attack our tissues, Stanford Medicine scientists have found.
030
Reposted by JN117
Eric Topol @erictopol.bsky.social · 13/11/2025
Our randomized, placebo-controlled trial of tirzepatide (Zepbound) for #LongCovid has already enrolled 500 participants of 1000 planned in less than 2 weeks! longcovid.scripps.edu/locitt-t/
longcovid.scripps.edu
LoCITT-T - Long COVID Treatment Trial
The Long COVID Treatment Trial-Tirzepatide (LoCITT-T) is investigating the efficacy of repurposing this drug to treat Long COVID.
620451
JN117 @jn117.bsky.social · 12/11/2025
I do not see the product on sale yet. No pricing was given.
000
JN117 @jn117.bsky.social · 12/11/2025
In clinical testing, the RSV test had 94% positive agreement with PCR for subjects within 5 days of symptom onset. www.accessdata.fda.gov/cdrh_docs/re...
100
JN117 @jn117.bsky.social · 12/11/2025
Interestingly, the test is licensed for people 6 months and older, so it includes a swab guard to prevent the swab from going deeper than intended.
100
JN117 @jn117.bsky.social · 12/11/2025
Unfortunately, no pictures of the actual test cartridge, but the FDA summary of decision shows some diagrams. It has two side-by-side test strips--one with Flu & COVID and the other with RSV. www.accessdata.fda.gov/cdrh_docs/re...
100
JN117 @jn117.bsky.social · 12/11/2025
October 27, 2027 -- FlowFlex introduced first US-approved RSV+Flu+COVID home test. Product is made in their new San Diego, CA facility. Press release: www.aconlabs.com/acon-laborat... @danielgriffinmdphd.bsky.social
120